Alumis(ALMS)
SOUTH SAN FRANCISCO, CABiotechnology
Focus: Alumis is a publicly-traded biotech company focused on autoimmune and immunological treatments, operating at a mid-cap scale with a heavily R&D-focused business model.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
23+8 this month
Growing — net +8 jobs in 30d
10 jobs added vs 2 removed. Steady team buildout.
Should You Work at Alumis?
AI assessmentHigh-risk, high-reward opportunity for scientists seeking immuno-oncology expertise and pipeline catalysts, but unsuitable for those prioritizing stability or near-term career advancement.
Why Work Here
- Leading pipeline in immunology with 3 Phase 3 programs (envudeucitinib and ESK-001 for plaque psoriasis) offering clear clinical development visibility
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$24M
Key Products
envudeucitinib
Growing
Growth
Lead Phase 3 program with 2 active trials; near-term data catalyst expected to define company trajectory.
Help build intelligence for Alumis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.